

Salmonella enterica Serovar Panama, an Understudied Serovar Responsible for Extraintestinal Salmonellosis Worldwide

Caisey Pulford, Blanca Perez-Sepulveda, Ella Rodwell, François-Xavier Weill, Kate Baker, Jay Hinton

► **To cite this version:**

Caisey Pulford, Blanca Perez-Sepulveda, Ella Rodwell, François-Xavier Weill, Kate Baker, et al.. Salmonella enterica Serovar Panama, an Understudied Serovar Responsible for Extraintestinal Salmonellosis Worldwide. Infection and Immunity, American Society for Microbiology, 2019, 87 (9), pp.e00273-19. 10.1128/IAI.00273-19 . pasteur-02481860

HAL Id: pasteur-02481860

<https://hal-pasteur.archives-ouvertes.fr/pasteur-02481860>

Submitted on 17 Feb 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.





Salmonella enterica Serovar Panama, an Understudied Serovar Responsible for Extraintestinal Salmonellosis Worldwide

 Caisey V. Pulford,^a Blanca M. Perez-Sepulveda,^a Ella V. Rodwell,^a François-Xavier Weill,^b Kate S. Baker,^a Jay C. D. Hinton^a

^aFunctional and Comparative Genomics, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom

^bInstitut Pasteur, Unité des Bactéries Pathogènes Entériques, Paris, France

ABSTRACT In recent years nontyphoidal *Salmonella* has emerged as one of the pathogens most frequently isolated from the bloodstream in humans. Only a small group of *Salmonella* serovars cause this systemic infection, known as invasive nontyphoidal salmonellosis. Here, we present a focused minireview on *Salmonella enterica* serovar Panama, a serovar responsible for invasive salmonellosis worldwide. *S. Panama* has been linked with infection of extraintestinal sites in humans, causing septicemia, meningitis, and osteomyelitis. The clinical picture is often complicated by antimicrobial resistance and has been associated with a large repertoire of transmission vehicles, including human feces and breast milk. Nonhuman sources of *S. Panama* involve reptiles and environmental reservoirs, as well as food animals, such as pigs. The tendency of *S. Panama* to cause invasive disease may be linked to certain serovar-specific genetic factors.

KEYWORDS invasive nontyphoidal *Salmonella*, *Salmonella*, *Salmonella enterica* serovar Panama

Salmonellosis is a disease caused by the enteric pathogen *Salmonella enterica*, a species that includes 2,637 different serovars (1). The various clinical presentations of *Salmonella* disease in humans include enteric fever, gastroenteritis, extraintestinal complications, and a chronic carrier state (2, 3). The clinical manifestation of *Salmonella* is dependent on a number of features, including host immune status (reviewed in reference 4), as well as factors specific to the *Salmonella* pathovariant that is causing the infection (5). Certain pathogen factors are associated with clinical presentation, including serovar and certain core and accessory genome components, such as the presence of plasmids, prophages, virulence factors, and antimicrobial resistance genes (6). In this review, we focus on *Salmonella enterica* serovar Panama, which has a strong association with invasive disease (7) and is a rarely discussed serovar that has global public health relevance. We review the global epidemiology, as well as the clinical picture, the transmission vehicles, and antimicrobial resistance, and put them into the context of our current genomic understanding.

GLOBAL DISEASE BURDEN AND EPIDEMIOLOGY

In 1931, an unknown bacterium caused widespread foodborne diarrheal disease among American soldiers stationed at the Panama Canal. A full microbiological investigation was conducted, and the organism was identified as a “not previously described *Salmonella*,” which was subsequently named *S. Panama* (8). Since initial isolation and serological characterization, *S. Panama* has been implicated in numerous geographically localized outbreaks of gastrointestinal and extraintestinal disease around the globe (9).

French territories in the Americas. *S. Panama* is responsible for a significant proportion of the total *Salmonella* disease burden worldwide and is a leading cause of

Citation Pulford CV, Perez-Sepulveda BM, Rodwell EV, Weill F-X, Baker KS, Hinton JCD. 2019. *Salmonella enterica* serovar Panama, an understudied serovar responsible for extraintestinal salmonellosis worldwide. *Infect Immun* 87:e00273-19. <https://doi.org/10.1128/IAI.00273-19>.

Editor Helene L. Andrews-Polymeris, Texas A&M University Health Science Center

Copyright © 2019 Pulford et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Jay C. D. Hinton, jay.hinton@liv.ac.uk.

Accepted manuscript posted online 1 July 2019

Published 21 August 2019

invasive nontyphoidal salmonellosis in French territories of America located in the Caribbean and South America (7, 10, 11). Between 1972 and 1974, *S. Panama* was the major *Salmonella* serovar isolated from human fecal samples in Martinique (10). Two decades later, a study focused on pediatric salmonellosis in Martinique identified *S. Panama* as the most commonly isolated *Salmonella* serovar, accounting for 35% of all cases between 1990 and 1994 (11). Similarly, in French Guiana, *S. Panama* was the most frequent *Salmonella* serovar acquired by humans, accounting for 12.9% of all cases of *Salmonella* infection in 2011 (12). More recently, *S. Panama* was listed as the *Salmonella* serovar most frequently isolated from pediatric blood samples in Guadeloupe, contributing to one-third of all cases of *Salmonella* infection between 2010 and 2014 (7), and univariate analysis showed *S. Panama* was associated with causing disease in children older than 6 months of age ($P = 0.002$) (7). These examples demonstrate the significant impact that *S. Panama* has on public health in French territories in the Americas and shows that *S. Panama* causes extraintestinal infection and gastrointestinal disease, particularly in children. Although more extensive work needs to be done, no evidence for antimicrobial resistance in *S. Panama* exists in these regions.

Latin America. *S. Panama* causes a significant proportion of the salmonellosis burden in Latin America, which in the 2000s was 3.5 cases confirmed by serotyping per 100,000 people (9). As early as the 1950s, 41 (12%) of 357 human *Salmonella* isolates collected in Maracaibo, Venezuela, were *Salmonella* serovar Panama. Interestingly, 15 isolates came from patients suffering from gastroenteritis, 4 came from individuals with enteric fever, and 22 came from healthy carriers, indicating that *S. Panama* could be carried asymptotically (13).

Historically, an outbreak of *S. Panama* in Chile originated from river water in Santiago in 1975 (14). By 1978, the serovar had infiltrated almost the entire country, expanding southward to Punta Arenas and northward toward Arica. The resulting human epidemic across Chile lasted for 4 years and involved the isolation of *S. Panama* from food, animals, and water, demonstrating the ability of the serovar to spread rapidly and survive outside of the human host. The majority of clinical cases involved children under 15 months of age with self-limiting diarrheal disease. However, examples of bacteremia and meningitis were also reported (14).

S. Panama continues to be isolated periodically in Chile and other parts of Latin America. According to global *Salmonella* monitoring compiled by the World Health Organization between 2001 and 2007, *S. Panama* was the ninth most common serovar isolated in Latin America (9). In 2007, *S. Panama* was responsible for 1% of 3,439 cases of *Salmonella* infection across Argentina, Brazil, Chile, and Costa Rica (9). In Colombia, *S. Panama* was the fifth most common serovar isolated from patients between 2005 and 2011 (15). Rapid dissemination of *S. Panama* around Chile in the 1970s, and the consistent reporting of the serovar among the top 10 that cause human disease post-2000, highlight the persistent burden of *S. Panama* in Latin America.

Asia. In Asia, *S. Panama* was the 11th most frequently isolated *Salmonella* serovar in humans between 2001 and 2007 (9). In 2001, 4% of salmonellosis cases in Thailand were caused by *S. Panama*, dropping to 3% in 2007 (9). In Tokyo, Japan, *S. Panama* was the third most common *Salmonella* serovar between 1974 and 1979, accounting for 5% of cases of *Salmonella* infection, and was commonly isolated from asymptomatic people (16). In Taiwan, where *S. Panama* causes 7% of the clinical cases of salmonellosis, *S. Panama* causes a higher rate of bacteremia in children under 5 years of age than other serovars, such as *Salmonella enterica* serovar Enteritidis (17). These findings demonstrate that *S. Panama* is an important public health issue in Asia.

Europe and the United States of America. Historically, *S. Panama* has caused a significant proportion of the salmonellosis cases in Europe, particularly related to the pig industry, and in the United States, where *S. Panama* has been implicated in several hospital and statewide outbreaks associated with a variety of food sources (18, 30, 98). The serovar was introduced into the United Kingdom during World War II as a result of unsterilized dried eggs imported from the United States being fed to pigs (18). Humans




FIG 1 Overview of the clinical presentations caused by *S. Panama* in adults and children according to the published literature, as follows: baby, brain abscess (36), meningitis (8, 14, 36, 38–43, 45), throat infection (35), septic arthritis (91), and osteomyelitis with sickle cell disease (92); adult, acute respiratory distress syndrome (93), pleuritic in Hodgkin's disease (94), aneurysm of the distending aorta (95), osteomyelitis (40, 92), pelvic inflammatory disease (96), Bartholin's abscess (37), knee joint empyema (40), and septic thrombophlebitis (97).

have also been involved in the spread of *S. Panama* during hospital outbreaks in France and in other Western European countries during the 1960s and 1970s (19, 20). Over this period, there was a 3-fold increase in *S. Panama* cases in the United Kingdom, which led to a doubling of the number of salmonellosis cases (18). Subsequently, between 1969 and 1984, *S. Panama* was one of the top five serovars responsible for invasive disease in the United Kingdom (21). It is thought that these isolates were exposed to high antibiotic selective pressure in humans or food animals and consequently became resistant to antibiotics via acquisition of many types of plasmids (22–28). Elsewhere in the European Union, *S. Panama* was reported among the top 10 most frequently isolated serovars during 2012, following 706 confirmed cases of *S. Panama* salmonellosis associated with outbreaks in Germany and Italy (29). Sporadic outbreaks of *S. Panama* salmonellosis also occurred in Switzerland (1972), Hungary (1979), Spain (1998), and the Netherlands (2008) (30–33). *S. Panama* maintained its ranking in the top 20 serovars associated with salmonellosis in the European Union until 2017, when it was replaced by other serovars (*Salmonella enterica* serovar Brandenburg, *Salmonella enterica* serovar Kottbus, and *Salmonella enterica* serovar Coeln) (34).

CLINICAL PICTURE IN HUMANS

Although *S. Panama* can cause gastrointestinal infection in humans (9), the serovar is more widely known for its ability to cause invasive disease and to colonize extraintestinal sites. For most salmonellae, extraintestinal colonization refers to bloodstream infection (2). However, *S. Panama* can also invade specific body sites, causing atypical presentations, including throat infection, brain abscess, and Bartholin's abscess (35–37) (summarized in Fig. 1). These unexpected symptoms of *S. Panama* infection can impede diagnosis and delay treatment.

The clinical presentation of *S. Panama* disease varies between adults and children

(Fig. 1). A common complication of neonatal *S. Panama* infection is the development of *Salmonella* meningitis (8, 14, 36, 38–45), a lethal disease that has previously been linked to localized outbreaks in hospital maternity wards (8, 31). For example, *S. Panama* was recovered from 138 babies, new mothers, and staff during an outbreak of salmonellosis in a neonatal nursery in Michigan in 1934 to 1944 that resulted in 18 fatalities due to *Salmonella* meningitis (8). Similar outbreaks have historically occurred in other countries, including Germany, where a hospital outbreak in a maternity unit caused prolonged contamination despite radical disinfection of the entire ward (46).

S. Panama causes more cases of clinically invasive disease in humans than most *Salmonella* serovars. Historically, *S. Panama* infections have been 11 times more likely to cause invasive disease than those by other serovars in Martinique (10, 11). In England, 7% of all *S. Panama* isolates were isolated from extraintestinal sites compared to 2% of *Salmonella enterica* serovar Typhimurium and 3% of *S. Enteritidis* isolates (21). In Taiwan, 70% of *S. Panama* isolates were isolated from invasive disease compared to 12% of *S. Enteritidis* isolates (47). In addition to these epidemiologically suggestive data, multivariate analysis has recently confirmed the association of *S. Panama* with clinically invasive infection ($P < 0.001$) as part of a retrospective study of *Salmonella* infections in children living in Guadeloupe (7). A gnotobiotic-mouse model has been described for *S. Panama* (48), which could help to elucidate the mechanisms behind the increased invasiveness.

TRANSMISSION VEHICLES

Wild reptiles are the natural reservoir for *S. Panama* in Latin America (12, 49–52). A study focusing on the frequency and host distribution of *Salmonella* serovars in reptiles and amphibians captured in the Republic of Panama between 1965 and 1967 showed that 2.6% of 78 *Salmonella* isolates were serovar Panama (49). In a subsequent study (1966 to 1969), 6.8% of *Salmonella* organisms isolated from neotropical lizards in Panama were *S. Panama* (50). In the past decade, a high prevalence of *Salmonella* has been found in the largest lizards in South America (Tegu lizards), and 3% of the isolates were classified as *S. Panama* (51). In French Guiana, where *S. Panama* was the most frequently isolated human-associated serovar in 2011, the serovar was also isolated from wild reptiles (12). Reptiles are likely to be an important source for transmission of *S. Panama* in regions of the world where many lizards and other reptiles are present in and around households. A recent survey of *Salmonella* strains carried by African venomous snakes did not isolate *S. Panama* (53).

In addition to reptiles, *S. Panama* has also been isolated from other wildlife species and companion animals. A study on pouched wild birds found *S. Panama* in cloacal swabs of chestnut-capped blackbirds in Rio de Janeiro, Brazil (54). In regard to companion animals, *S. Panama* was isolated from a household dog in Taiwan (55). *S. Panama* contamination has been found in birds and fish tanks sampled from pet shops and households in Trinidad (56). Wildlife, therefore, represent a potential reservoir for *S. Panama* dissemination.

In Europe, *S. Panama* infection is primarily a foodborne disease, with the main transmission vehicles being pork-derived products, including cured meat, minced pork, and sausages (57). The transmission pathway for *S. Panama* begins in animal feed, from where it can enter porcine and poultry animal reservoirs and move into animal food products, eventually infecting humans (18).

At the animal level, *S. Panama* was found in 2.08% of 200 abattoir pigs sampled in Budapest, Hungary (58), and has been found in cattle and swine in Germany (59). Outside Europe, *S. Panama* has been identified in beef and dairy herds in Argentina (60) and is the second most common *Salmonella* serovar to be isolated from swine finishing herds in Brazil (61).

S. Panama is also recognized as a contaminant in food-processing facilities and retail establishments globally, including butcher shops (62), public markets (63), meat vans (64), and slaughterhouses (65). The process of manufacturing pork-derived products includes several steps designed to result in a microbiologically safe, shelf-stable prod-

uct by tightly controlling physicochemical conditions, such as salt and nitrate concentrations, pH, water activity, and temperature (66). However, *Salmonella* viability throughout this curing process has been reported, including the presence of *S. Panama* in salami (67, 68). In the Netherlands, *S. Panama* has additionally been implicated in the contamination of cattle-derived food products and was one of the three *Salmonella* serovars most frequently isolated from mincemeat over a 13-month period. Interestingly, mincemeat from slaughterhouses was more likely to contain *Salmonella* than mincemeat derived from slaughtering completed at butcher shops (69). Food-processing facilities themselves can play a role in the contamination of animal food products with *S. Panama*.

The impact of *S. Panama* entering the human food chain can be seen in an outbreak of salmonellosis that affected 300 people who had eaten contaminated roast pork in the United Kingdom in 1970. *S. Panama* was implicated as the etiological agent (18). *S. Panama* has also caused several foodborne outbreaks between 1990 and 1999 in Asturias, Spain, and isolates were collected from gastroenteritis and septicemia patients who had consumed contaminated fish puddings, cooked octopus, and cream cakes (32). Other studies have linked *S. Panama* infections to consumption of goat cheese, vegetables, beef, poultry, eggs, fruit juice, and shellfish (14, 33, 70).

In addition to the usual fecal-oral transmission route of *Salmonella* in humans, breast milk has also been suggested as a vector for *S. Panama* (71). A study demonstrated that *S. Panama* can infect the human mammary duct, can be shed for at least 2 weeks, and can remain stable during storage of breast milk at 4°C (71). Furthermore, it is possible that a case of meningitis in an exclusively breastfed 4-month-old patient was contracted from breast milk that was contaminated with an antimicrobial-susceptible *S. Panama* isolate (41).

ANTIMICROBIAL RESISTANCE

Burden of antimicrobial resistance in *S. Panama*. Antimicrobial resistance (AMR) is an important public health concern (72). There are conflicting reports in the literature relating to the AMR status of the *S. Panama* serovar, with studies in Italy and Brazil reporting low levels of antibiotic resistance (41, 73). They are supported by further reports from Martinique, where 91% of *S. Panama* isolates were susceptible to beta-lactams (11), and Guadeloupe, where all *Salmonella* serovars demonstrated high overall susceptibility to antibiotics (7). In contrast, other studies have seen higher levels of resistance in *S. Panama*, particularly against tetracycline (e.g., 67%) and chloramphenicol (e.g., 67%) since the 1980s (24, 47, 59, 74–76). Antibiotic stewardship promises to be an effective tool for decreasing antimicrobial resistance in the *S. Panama* serovar. For example, following a ban on tetracycline use in the pork industry in the Netherlands, *S. Panama* tetracycline resistance dropped from 90% to 1% (24).

In Asia, *S. Panama* has been associated with high levels of AMR since 1980, when 58% of the *S. Panama* isolates from Tokyo were resistant to at least one antibiotic agent (77). This figure appears to be on the rise. By the turn of the millennium, 83% of domestic and imported *S. Panama* isolates from cases in Tokyo were multidrug resistant. Similarly, in Taiwan, the serovar also exhibited resistance to multiple antibiotics, including cotrimoxazole (67%), ampicillin (56%), streptomycin (56%), kanamycin (56%), and gentamicin (45%) (74). The high proportion of *S. Panama* isolates that show AMR should be considered by clinicians working in Asia and by health care practitioners globally when treating Asian-travel-associated salmonellosis cases caused by *S. Panama*.

Genomic markers and trends in antimicrobial resistance. A large proportion of *S. Panama* antimicrobial resistance has been associated with plasmid carriage ($P = 0.012$), class 1 integron presence, and transmissible drug resistance (R) factors (22, 47, 74, 78). Resistance to tetracycline, for example, has often been mediated by the R factor R1 in *S. Panama* (26). Such R factors have been implicated in the transfer of multiple antimicrobial resistance genes, usually simultaneously, between *S. Panama* strains and other bacteria. However, an isolate from an epidemic of *S. Panama* infection in Paris showed unusual patterns of transferable resistance, which may extend to other strains in the *S. Panama* serovar. The isolate was able to transfer genes involved in antimicrobial resistance singly or in pairs, rather than as one antibiotic resistance

cassette. The proposed mechanism involved the simultaneous transfer of several discrete genetic elements that were able to coexist stably and to replicate noncompetitively in *S. Panama*. The authors suggested that frequent cotransfer of genetic elements may be propagated by conjugative-transfer machinery (27).

INVASIVE DISEASE—GENOMIC INFERENCES IN *S. PANAMA*

Evolutionary history and virulence. The study of evolutionary history may explain why *S. Panama* is associated with invasive disease. The majority of salmonellae that cause disease in humans belong to *S. enterica* subsp. *enterica*, which is further divided into two main clades, A and B, and a number of smaller clades (79). Phylogenetically, *S. Panama* is in clade B, which is associated with increased levels of clinically invasive disease (53, 80, 81). Another review of the population structure within *S. enterica* found that *S. Panama* is in lineage 3 (equivalent to the above-mentioned clade B) (82).

The evolutionary history of *S. Panama* was studied by Selander et al. (83), who used multilocus enzyme electrophoresis to assess the relationships among *Salmonella* serovars that cause invasive disease. It was proposed that *S. Panama* evolved from the same ancestors that gave rise to *Salmonella enterica* serovar Paratyphi, *Salmonella enterica* serovar Sendai (which causes enteric fever), and *Salmonella enterica* serovar Miami (83). In the current era of genomically informed epidemiological analysis, phylogenetic methods can be used to understand the evolutionary history of *Salmonella*. However, no large-scale phylogenetic study has yet been conducted on *S. Panama*, and only one complete *S. Panama* genome sequence (from strain ATCC 7378; GenBank accession no. CP012346) is available (84). As part of the current review, virulence genes were identified in the complete genome of *S. Panama* strain ATCC 7378 using the program ABRicate v0.8.10 (<https://github.com/tseemann/abricate>) against a virulence factor database (85) with default parameters. In total, 131 virulence-associated genes were identified. The analysis confirmed the presence of typical *Salmonella* virulence determinants, including type III secretion systems, type III effector proteins, fimbriae, and flagella. Of interest, *S. Panama* was also found to carry the cytolethal distending toxin B gene (*cdtB*), which is characteristic of *S. enterica* clade B and the highly invasive *Salmonella enterica* serovar Typhi (53, 80, 81). A more detailed, epidemiologically representative analysis is required to further elucidate the uniqueness of the *S. Panama* serovar.

Accessory genome and virulence. Generally, plasmids play a key role in systemic *Salmonella* infection, but little is known about the plasmid complement of the *S. Panama* serovar. In the small number of available studies, it is reported that *S. Panama*, including the above-mentioned *S. Panama* ATCC 7378, does not commonly carry the large plasmids that have previously been associated with virulence in other *Salmonella* serovars (41). Rather, *S. Panama* strains carry a heterogeneous population of plasmids (86). Prophages can also make significant contributions to *Salmonella* virulence (87, 88), but only one study has reported the presence of prophages in *S. Panama* (84). The *Salmonella* RE-2010 prophage was identified in the genome of *S. Panama* ATCC 7378. The prophage (also known as EIPhIS) has also been found in *S. Enteritidis*, where it has been associated with specific phylogenetic clusters (89, 90). The importance of *S. Panama* for public health globally necessitates that a concerted comparative genomic analysis be conducted in the future.

PERSPECTIVES

S. Panama is a globally relevant pathogen that has consistently been reported as one of the most frequently isolated *Salmonella* serovars over the past 70 years. The proportion of clinical cases caused by *S. Panama* is particularly high in French territories in the Americas, where it is associated with invasion of extraintestinal sites, particularly in infants. Reptiles act as natural reservoirs for *Salmonella* in these regions, and it has been speculated that the large numbers of reptiles found in and around homes in tropical regions of America lead to high levels of *S. Panama* transmission to humans. The serovar was also introduced into Europe, where it spread through the pork industry

and caused hospital outbreaks in the 1960s and 1970s. *S. Panama* continues to contribute to the global disease burden caused by salmonellae.

It is important to highlight the unusual clinical presentation of *S. Panama* in different patient populations to avoid delays in patient treatment. Clinicians and researchers should remain aware of the potential for increasing levels of antimicrobial resistance in the serovar, as has been described in Asia. Unraveling the molecular epidemiology and evolutionary history of *S. Panama* is the obvious next step in understanding more about this rarely studied serovar that continues to cause invasive salmonellosis worldwide.

ACKNOWLEDGMENTS

Caisey V. Pulford is supported by a Fee Bursary Award from the Institute of Integrative Biology at the University of Liverpool and by a John Lennon Memorial Scholarship from the University of Liverpool. Kate S. Baker is funded by a Wellcome Trust Clinical Research Career Development Fellowship (106690/A/14/Z). Jay C. D. Hinton is funded by a Wellcome Trust Senior Investigator Award (106914/Z/15/Z).

REFERENCES

- Issenhuth-Jeanjean S, Roggentin P, Mikoleit M, Guibourdenche M, de Pinna E, Nair S, Fields PI, Weill F-X. 2014. Supplement 2008–2010 (no. 48) to the White-Kauffmann-Le Minor scheme. *Res Microbiol* 165:526–530. <https://doi.org/10.1016/j.resmic.2014.07.004>.
- Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. 2015. Global burden of invasive nontyphoidal *Salmonella* disease. *Emerg Infect Dis* 21:941–949. <https://doi.org/10.3201/eid2106.140999>.
- Crump JA, Luby SP, Mintz ED. 2004. The global burden of typhoid fever. *Bull World Health Organ* 82:346–353.
- Gilchrist JJ, MacLennan CA. 2019. Invasive nontyphoidal *Salmonella* disease in Africa. *EcoSal Plus* 8. <https://doi.org/10.1128/ecosalplus.ESP-0007-2018>.
- de Jong HK, Parry CM, van der Poll T, Wiersinga WJ. 2012. Host-pathogen interaction in invasive salmonellosis. *PLoS Pathog* 8:e1002933. <https://doi.org/10.1371/journal.ppat.1002933>.
- Fierer J, Guiney DG. 2001. Diverse virulence traits underlying different clinical outcomes of *Salmonella* infection. *J Clin Invest* 107:775–780. <https://doi.org/10.1172/JCI12561>.
- Guyomard-Rabenirina S, Muanza B, Bastian S, Malpote E, Jestin P, Guerin M, Talarmin A, Weill F-X, Legrand A, Breurec S. 2018. *Salmonella enterica* serovars Panama and Arechavaleta: risk factors for invasive nontyphoidal *Salmonella* disease in Guadeloupe, French West Indies. *Am J Trop Med Hyg* 99:584–589. <https://doi.org/10.4269/ajtmh.18-0192>.
- Leeder FS. 1956. An epidemic of *Salmonella panama* infections in infants. *Ann N Y Acad Sci* 66:54–60. <https://doi.org/10.1111/j.1749-6632.1956.tb40102.x>.
- Hendriksen RS, Vieira AR, Karlsmose S, Lo Fo Wong DMA, Jensen AB, Wegener HC, Aarestrup FM. 2011. Global monitoring of *Salmonella* serovar distribution from the World Health Organization Global Foodborne Infections Network Country Data Bank: results of quality assured laboratories from 2001 to 2007. *Foodborne Pathog Dis* 8:887–900. <https://doi.org/10.1089/fpd.2010.0787>.
- Papa F. 1976. Contribution to the study of *Salmonella* in Martinique. Evolution during 1972, 1973 and 1974. *Bull Soc Pathol Exot Filiales* 69:121–125.
- Olive C, Mansuy JMM, Desbois N, Roche B, Cecile W, Saint-Aime C, Jouannelle J. 1996. *Salmonella panama* en Martinique: aspects épidémiologiques et cliniques chez l'enfant hospitalisé. *Méd Mal Infect* 26: 590–593. [https://doi.org/10.1016/S0399-077X\(96\)80078-3](https://doi.org/10.1016/S0399-077X(96)80078-3).
- Gay N, Le Hello S, Weill F-X, de Thoisy B, Berger F. 2014. *Salmonella* serotypes in reptiles and humans, French Guiana. *Vet Microbiol* 170: 167–171. <https://doi.org/10.1016/j.vetmic.2014.01.024>.
- Le Minor L, Le Minor S, Fossaert H, Maso Dominguez J. 1954. *Salmonella* isolated in Maracaibo (Venezuela) in 1952–1953. *Bull Soc Pathol Exot Filiales* 47:775–781.
- Cordano AM, Virgilio R. 1996. Evolution of drug resistance in *Salmonella panama* isolates in Chile. *Antimicrob Agents Chemother* 40:336–341. <https://doi.org/10.1128/AAC.40.2.336>.
- Rodriguez EC, Diaz-Guevara P, Moreno J, Bautista A, Montano L, Realpe ME, Della Gaspera A, Wiesner M. 2017. Laboratory surveillance of *Salmonella enterica* from human clinical cases in Colombia 2005–2011. *Enferm Infect Microbiol Clin* 35:417–425. <https://doi.org/10.1016/j.eimc.2016.02.023>.
- Horiuchi S, Inagaki Y, Nakaya R, Goto N, Yoshida Y, Kusunoki J, Ito T, Ohashi M. 1989. Serovars, antimicrobial resistance and conjugative R plasmids of *Salmonella* isolated from human during the period of 1966–1986 in Tokyo. *Kansenshogakuzasshi* 63:352–362. <https://doi.org/10.11150/kansenshogakuzasshi1970.63.352>.
- Tsai KS, Yang YJ, Wang SM, Chiou CS, Liu CC. 2007. Change of serotype pattern of group D non-typhoidal *Salmonella* isolated from pediatric patients in southern Taiwan. *J Microbiol Immunol Infect* 40:234–239.
- Lee JA. 1974. Recent trends in human salmonellosis in England and Wales: the epidemiology of prevalent serotypes other than *Salmonella typhimurium*. *J Hyg* 72:185–195. <https://doi.org/10.1017/S0022172400023391>.
- Le Minor L, Le Minor S. 1981. Origin and frequency of the serotypes of *Salmonella* isolated in France and received in the French National Center during the years 1977–1979. *Rev Epidemiol Sante Publique* 29:45–55.
- Cherubin CE. 1981. Antibiotic resistance of *Salmonella* in Europe and the United States. *Rev Infect Dis* 3:1105–1126. <https://doi.org/10.1093/clinids/3.6.1105>.
- Wilkins EG, Roberts C. 1988. Extraintestinal salmonellosis. *Epidemiol Infect* 100:361–368. <https://doi.org/10.1017/S095026880006711x>.
- Manten A, Guinee PA, Kampelmacher EH, Voogd CE. 1971. An eleven-year study of drug resistance in *Salmonella* in the Netherlands. *Bull World Health Organ* 45:85–93.
- Guinee PA, Scholtens RT, Willems HM. 1967. Influence of resistance-factors on the phage types of *Salmonella panama*. *Antonie Van Leeuwenhoek* 33:30–40. <https://doi.org/10.1007/BF02045531>.
- van Leeuwen WJ, Voogd CE, Guinee PA, Manten A. 1982. Incidence of resistance to ampicillin, chloramphenicol, kanamycin, tetracycline and trimethoprim of *Salmonella* strains isolated in The Netherlands during 1975–1980. *Antonie Van Leeuwenhoek* 48:85–96. <https://doi.org/10.1007/BF00399490>.
- Guinee PA. 1969. Phage types and resistance factors in *S. panama* strains from various countries. *Zentralbl Bakteriol Orig* 209:331–336.
- Guinee PA. 1968. R transfer to *S. panama* in vitro and in vivo. *Antonie Van Leeuwenhoek* 34:93–98. <https://doi.org/10.1007/BF02046419>.
- Bouanchaud DH, Chabbert YA. 1969. Stable coexistence of three resistance factors (fr-) in *Salmonella panama* and *Escherichia coli* K12. *J Gen Microbiol* 58:107–113. <https://doi.org/10.1099/00221287-58-1-107>.
- Avril JL, Dabernat HJ, Gerbaud GR, Horodniceanu T, Lambert-Zechovsky N, Le Minor S, Mendez B, Chabbert YA. 1977. R plasmids incompatibility groups in epidemic *Salmonella*. *Ann Microbiol* 128:165–175.
- European Food Safety Authority and European Centre for Disease Prevention and Control. 2012. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2010. *Euro Surveill* 17:20113.
- Ernst R, Gurdan P. 1973. *Salmonella-panama* epidemic in Basel, spring 1972, from the veterinary viewpoint. *Schweiz Arch Tierheilkd* 115:8–15.

31. Lantos J, Fekete J, Kiraly K. 1981. R-plasmid study of an outbreak caused by multiresistant strains of *Salmonella panama*. *Acta Microbiol Acad Sci Hung* 28:211–217.
32. Soto SM, Guerra B, Del Cerro A, González-Hevia MA, Mendoza MC. 2001. Outbreaks and sporadic cases of *Salmonella* serovar Panama studied by DNA fingerprinting and antimicrobial resistance. *Int J Food Microbiol* 71:35–43. [https://doi.org/10.1016/S0168-1605\(01\)00553-0](https://doi.org/10.1016/S0168-1605(01)00553-0).
33. Noël H, Hofhuis A, De Jonge R, Heuvelink AE, De Jong A, Heck M, De Jager C, van Pelt W. 2010. Consumption of fresh fruit juice: how a healthy food practice caused a national outbreak of *Salmonella Panama* gastroenteritis. *Foodborne Pathog Dis* 7:375–381. <https://doi.org/10.1089/fpd.2009.0330>.
34. European Food Safety Authority and European Centre for Disease Prevention and Control. 2018. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017. *EFSA J* 16:262.
35. Varela G, Aguilar Ochoa A. 1953. *Salmonella panama* and *Escherichia coli* 055 in the throat of infants. *Rev Inst Salubr Enferm Trop* 13:331–333.
36. Kostiala AA, Westerstrahle M, Mutilainen M. 1992. Neonatal *Salmonella panama* infection with meningitis. *Acta Paediatr* 81:856–858. <https://doi.org/10.1111/j.1651-2227.1992.tb12122.x>.
37. Cummins AJ, Atia WA. 1994. Bartholin's abscess complicating food poisoning with *Salmonella panama*: a case report. *Genitourin Med* 70: 46–48. <https://doi.org/10.1136/sti.70.1.46>.
38. Talon P, Schneller E, Stoll C. 1985. *Salmonella panama* responsible for meningitis secondary to febrile gastroenteritis in a 3-month-old infant. *Pediatrics* 40:223–227.
39. Borderon JC, Prieur D, Huguet B. 1981. Cefotaxime CSF levels in children with purulent meningitis. *Nouv Presse Med* 10:580–584.
40. Oprea W. 1975. Infection with "enteritis salmonella" at non-intestinal sites. *Dtsch Med Wochenschr* 100:1425–1428. <https://doi.org/10.1055/s-0028-1106400>.
41. Carneiro MRP, de Patrício MIA, Jain S, Rodrigues DDP, Fracalanza S. 2018. Meningitis caused by *Salmonella enterica* serotype Panama in Brazil: first case reported. *Rev Soc Bras Med Trop* 51:244–246. <https://doi.org/10.1590/0037-8682-0367-2017>.
42. Elenga N, Cuadro E, Long L, Njuiyeyon F, Martin E, Kom-Tchameni R, Defo A, Razafindrakoto SH, Msrac Y, Henaff F, Mahamat A. 2017. *Salmonella enterica* serovar Panama meningitis in exclusive breastfeeding infants: report of 4 cases, clinical features and therapeutic challenges. *Medicine* 96:e6665. <https://doi.org/10.1097/MD.0000000000006665>.
43. Gericke D, Luchtrath H. 1951. A peculiar form of meningitis caused by *Salmonella panama*. *Med Klin* 46:862–865.
44. Coignet J, Tamalet J, Pons M, Passeron P, Chapoy P. 1971. 2 cases of neonatal meningitis caused by "*Salmonella panama*". *Mars Med* 108: 63–66.
45. Lăzărescu M, Mucuşă G, Pena J. 1971. Meningitis with *Salmonella panama* in infants. *Microbiol Parazitol Epidemiol* 16:429–432.
46. Kienitz M, Licht W, Richter M. 1977. Little epidemic caused by *Salmonella panama*. *Med Klin* 72:806–808.
47. Huang S-C, Chiu C-H, Chiou C-S, Yang Y-J. 2013. Multidrug-resistant *Salmonella enterica* serovar Panama carrying class 1 integrons is invasive in Taiwanese children. *J Formos Med Assoc* 112:269–275. <https://doi.org/10.1016/j.jfma.2012.02.011>.
48. Ruitenbergh EJ, Guinee PA, Kruyt BC, Berkvens JM. 1971. *Salmonella* pathogenesis in germ-free mice. A bacteriological and histological study. *Br J Exp Pathol* 52:192–197.
49. Kourany M, Myers CW, Schneider CR. 1970. Panamanian amphibians and reptiles as carriers of *Salmonella*. *Am J Trop Med Hyg* 19:632–638. <https://doi.org/10.4269/ajtmh.1970.19.632>.
50. Kourany M, Telford SR. 1981. Lizards in the ecology of salmonellosis in Panama. *Appl Environ Microbiol* 41:1248–1253.
51. Maciel BM, Argolo Filho RC, Nogueira SSC, Dias JCT, Rezende RP. 2010. High prevalence of *Salmonella* in tegu lizards (*Tupinambis merianae*), and susceptibility of the serotypes to antibiotics. *Zoonoses Public Health* 57:e26–e32. <https://doi.org/10.1111/j.1863-2378.2009.01283.x>.
52. Everard CO, Tota B, Bassett D, Ali C. 1979. *Salmonella* in wildlife from Trinidad and Grenada, W.I. *J Wildl Dis* 15:213–219. <https://doi.org/10.7589/0090-3558-15.2.213>.
53. Pulford CV, Wenner N, Redway ML, Rodwell EV, Webster HJ, Escudero R, Kröger C, Canals R, Rowe W, Lopez J, Hall N, Rowley PD, Timofte D, Harrison RA, Baker KS, Hinton J. 2019. The diversity, evolution and ecology of *Salmonella* in venomous snakes. *PLoS Negl Trop Dis* 13: e0007169. <https://doi.org/10.1371/journal.pntd.0007169>.
54. Matias CAR, Pereira IA, de Araújo MDS, Santos AFM, Lopes RP, Christakis S, Rodrigues DDP, Siciliano S. 2016. Characteristics of *Salmonella* spp. isolated from wild birds confiscated in illegal trade markets, Rio de Janeiro, Brazil. *Biomed Res Int* 2016:1–7. <https://doi.org/10.1155/2016/3416864>.
55. Tsai HJ, Huang HC, Lin CM, Lien YY, Chou CH. 2007. *Salmonellae* and *Campylobacters* in household and stray dogs in northern Taiwan. *Vet Res Commun* 31:931–939. <https://doi.org/10.1007/s11259-007-0009-4>.
56. Seepersadsingh N, Adesiyun AA. 2003. Prevalence and antimicrobial resistance of *Salmonella* spp. in pet mammals, reptiles, fish aquarium water, and birds in Trinidad. *J Vet Med Ser B* 50:488–493. <https://doi.org/10.1046/j.0931-1793.2003.00710.x>.
57. European Food Safety Authority and European Centre for Disease Prevention and Control. 2014. The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2012. *EFSA J* 12:3547. <https://doi.org/10.2903/j.efsa.2014.3547>.
58. Jayarao BM, Biro G, Kovacs S, Domjan H, Fabian A. 1989. Prevalence of *Salmonella* serotypes in pigs and evaluation of a rapid, presumptive test for detection of *Salmonella* in pig faeces. *Acta Vet Hung* 37:39–44.
59. Kempf G, Pietzsch O. 1977. Phage-typing and tetracycline resistance in *Salmonella panama* strains of animal origin in the Federal Republic of Germany (1969–1975). *Zentralbl Bakteriol Orig A* 238:370–378.
60. Bellinzoni RC, Blackhall J, Terzolo HR, Moreira AR, Auza N, Mattion N, Micheo GL, La Torre JL, Scodeller EA. 1990. Microbiology of diarrhoea in young beef and dairy calves in Argentina. *Rev Argent Microbiol* 22: 130–136.
61. Kich JD, Coldebella A, Mores N, Nogueira MG, Cardoso M, Fratamico PM, Call JE, Fedorka-Cray P, Luchansky JB. 2011. Prevalence, distribution, and molecular characterization of *Salmonella* recovered from swine finishing herds and a slaughter facility in Santa Catarina, Brazil. *Int J Food Microbiol* 151:307–313. <https://doi.org/10.1016/j.jfoodmicro.2011.09.024>.
62. Brisou B, Casano P, Chamfeuil R, Boudon A. 1975. Human meat-borne salmonellosis: epidemiological reflections on a bacteriological survey of the butchers' shops of a large town. *Rev Epidemiol Med Soc Sante Publique* 23:445–461.
63. Castillo A, Villarruel-López A, Navarro-Hidalgo V, Martínez-González NE, Torres-Vitela MR. 2006. *Salmonella* and *Shigella* in freshly squeezed orange juice, fresh oranges, and wiping cloths collected from public markets and street booths in Guadalajara, Mexico: incidence and comparison of analytical routes. *J Food Prot* 69:2595–2599. <https://doi.org/10.4315/0362-028X-69.11.2595>.
64. Smit MP, Noorder HJ. 1978. *Salmonella* in scrapings from meat vans. *Tijdschr Diergeneesk* 103:1174–1179.
65. von Altrock A, Schutte A, Hildebrandt G. 2000. Results of the German investigation in the EU project "Salmonella in Pork (Salinork)." 2. Investigations in a slaughterhouse. *Berl Munch Tierarztl Wochenschr* 113: 225–233.
66. Soto E, Hoz L, Ordóñez JA, Hierro E, Herranz B, López-Bote C, Cambero MI. 2008. Impact of feeding and rearing systems of Iberian pigs on volatile profile and sensory characteristics of dry-cured loin. *Meat Sci* 79:666–676. <https://doi.org/10.1016/j.meatsci.2007.10.031>.
67. Bonardi S, Bruini I, Bolzoni L, Cozzolino P, Pierantoni M, Brindani F, Bellotti P, Renzi M, Pongolini S. 2017. Assessment of *Salmonella* survival in dry-cured Italian salami. *Int J Food Microbiol* 262:99–106. <https://doi.org/10.1016/j.jfoodmicro.2017.09.016>.
68. Reynolds AE, Harrison MA, Rose-Morrow R, Lyon CE. 2001. Validation of dry cured ham process for control of pathogens. *J Food Sci* 66: 1373–1379. <https://doi.org/10.1111/j.1365-2621.2001.tb15217.x>.
69. Edel W, Van Leusden FM, Kampelmacher EH. 1978. *Salmonella* in minced meat from ten meat inspection services in the Netherlands. *Tijdschr Diergeneesk* 103:220–228.
70. Quesada A, Reginatto GA, Español AR, Colantonio LD, Burrone MS. 2016. Antimicrobial resistance of *Salmonella* spp isolated animal food for human consumption. *Rev Peru Med Exp Salud Publica* 33:32–44. <https://doi.org/10.17843/rpmesp.2016.331.1899>.
71. Chen T-L, Thien P-F, Liaw S-C, Fung C-P, Siu L-K. 2005. First report of *Salmonella enterica* serotype Panama meningitis associated with consumption of contaminated breast milk by a neonate. *J Clin Microbiol* 43:5400–5402. <https://doi.org/10.1128/JCM.43.10.5400-5402.2005>.
72. O'Neill J. 2014. Antimicrobial Resistance: tackling a crisis for the health and wealth of nations. Wellcome Trust, London, United Kingdom.
73. Lamanna A, Benci G, Alecci A. 1977. Sensitivity to chemoantibiotic therapy of new isolated salmonellae strains. *Ann Sclavo* 19:409–419.
74. Lee H-Y, Yang Y-J, Su L-H, Hsu C-H, Fu Y-M, Chiu C-H. 2008. Genotyping

- and antimicrobial susceptibility of *Salmonella enterica* serotype Panama isolated in Taiwan. *J Microbiol Immunol Infect* 41:507–512.
75. Matsushita S, Yamada S, Inaba M, Kusunoki J, Kudoh Y, Ohashi M. 1992. Serovar distribution and drug resistance of *Salmonella* isolated from imported and domestic cases in 1980–1989 in Tokyo. *Kansenshogakuzasshi* 66:327–339. <https://doi.org/10.11150/kansenshogakuzasshi1970.66.327>.
 76. Stephan R, Bulling E, Steinbeck A. 1977. The development of antibiotics resistance among *Salmonella* bacteria of animal origin in the Federal Republic of Germany and Berlin (West). 6th communication: 1975 annual report. *Zentralbl Bakteriol Orig A* 237:264–273.
 77. Matsushita S, Kawamura M, Takahashi M, Yokoyama K, Konishi N, Yanagawa Y, Kai A, Yamada S, Allarozumi S, Kudoh Y. 2001. Serovar-distribution and drug-resistance of *Salmonella* strains isolated from domestic and imported cases during 1995–1999 in Tokyo. *Kansenshogakuzasshi* 75:116–123. <https://doi.org/10.11150/kansenshogakuzasshi1970.75.116>.
 78. Rodríguez I, Martín MC, Mendoza MC, Rodicio MR. 2006. Class 1 and class 2 integrons in non-prevalent serovars of *Salmonella enterica*: structure and association with transposons and plasmids. *J Antimicrob Chemother* 58:1124–1132. <https://doi.org/10.1093/jac/dkl400>.
 79. Worley J, Meng J, Allard MW, Brown EW, Timme RE. 2018. *Salmonella enterica* phylogeny based on whole-genome sequencing reveals two new clades and novel patterns of horizontally acquired genetic elements. *mBio* 9:e02303-18. <https://doi.org/10.1128/mBio.02303-18>.
 80. den Bakker HC, Moreno Switt AI, Govoni G, Cummings CA, Ranieri ML, Degoricija L, Hoelzer K, Rodriguez-Rivera LD, Brown S, Bolchacova E, Furtado MR, Wiedmann M. 2011. Genome sequencing reveals diversification of virulence factor content and possible host adaptation in distinct subpopulations of *Salmonella enterica*. *BMC Genomics* 12:425. <https://doi.org/10.1186/1471-2164-12-425>.
 81. Parsons SK, Bull CM, Gordon DM. 2011. Substructure within *Salmonella enterica* subsp. *enterica* isolates from Australian wildlife. *Appl Environ Microbiol* 77:3151–3153. <https://doi.org/10.1128/AEM.02764-10>.
 82. Didelot X, Bowden R, Street T, Golubchik T, Spencer C, McVean G, Sangal V, Anjum MF, Achtman M, Falush D, Donnelly P. 2011. Recombination and population structure in *Salmonella enterica*. *PLoS Genet* 7:e1002191. <https://doi.org/10.1371/journal.pgen.1002191>.
 83. Selander RK, Beltran P, Smith NH, Helmuth R, Rubin FA, Kopecko DJ, Ferris K, Tall BD, Cravioto A, Musser JM. 1990. Evolutionary genetic relationships of clones of *Salmonella* serovars that cause human typhoid and other enteric fevers. *Infect Immun* 58:2262–2275.
 84. Yao K, Muruvanda T, Roberts RJ, Payne J, Allard MW, Hoffmann M. 2016. Complete genome and methylome sequences of *Salmonella enterica* subsp. *enterica* serovar Panama (ATCC 7378) and *Salmonella enterica* subsp. *enterica* serovar Sloterdijk (ATCC 15791). *Genome Announc* 4:e00133-16. <https://doi.org/10.1128/genomeA.00133-16>.
 85. Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, Jin Q. 2005. VFDB: a reference database for bacterial virulence factors. *Nucleic Acids Res* 33:D325–D328. <https://doi.org/10.1093/nar/gki008>.
 86. Stanley J, Baquar N, Burnens A. 1995. Molecular subtyping scheme for *Salmonella panama*. *J Clin Microbiol* 33:1206–1211.
 87. Lemire S, Figueroa-Bossi N, Bossi L. 2008. Prophage contribution to *Salmonella* virulence and diversity, p 159–192. *In* Schmidt H, Hensel M. (ed), *Horizontal gene transfer in the evolution of pathogenesis*. Cambridge University Press, Cambridge, United Kingdom.
 88. Wahl A, Battesti A, Ansaldo M. 2019. Prophages in *Salmonella enterica*: a driving force in reshaping the genome and physiology of their bacterial host? *Mol Microbiol* 111:303–316. <https://doi.org/10.1111/mmi.14167>.
 89. Graham RMA, Hiley L, Rathnayake IU, Jennison AV. 2018. Comparative genomics identifies distinct lineages of *S. Enteritidis* from Queensland, Australia. *PLoS One* 13:e0191042-15. <https://doi.org/10.1371/journal.pone.0191042>.
 90. Hanna LF, Matthews TD, Dinsdale EA, Hasty D, Edwards RA. 2012. Characterization of the ELPhIS prophage from *Salmonella enterica* serovar Enteritidis strain LK5. *Appl Environ Microbiol* 78:1785–1793. <https://doi.org/10.1128/AEM.07241-11>.
 91. Barczy J, Foldes G. 1990. Septic arthritis associated with childhood salmonellosis. *Orv Hetil* 131:979–980.
 92. van Cappelle HG, Veenendaal D, de Vogel PL. 1995. *Salmonella panama* osteomyelitis in an otherwise healthy patient. A case report. *Clin Orthop Relat Res* 321:235–238.
 93. Heysell SK, Thomas TA, Morrison AR, Barry M. 2008. *Salmonella panama* and acute respiratory distress syndrome in a traveler taking a proton pump inhibitor. *J Travel Med* 15:460–463. <https://doi.org/10.1111/j.1708-8305.2008.00258.x>.
 94. Edel W, van Schothorst M, van Leusden FM, Kampelmacher EH. 1978. Epidemiological studies on salmonella in a certain area (“Walcheren project”). III. The presence of salmonella in man, insects, seagulls and in foods, chopping-block scrapings from butcher’s shops, effluent of sewage treatment plants and drains of butcher’s shops. *Zentralbl Bakteriol Orig A* 242:468–480.
 95. Modai J, Robineau M, Brucker G, Veysier P, Neveux JY, Domart A. 1974. Septicemia caused by *Salmonella panama* and aneurysm of the descending aorta. *Ann Med Interne* 125:581–585.
 96. Kostiala AA, Ranta T. 1989. Pelvic inflammatory disease caused by *Salmonella panama* and its treatment with ciprofloxacin. Case report. *Br J Obstet Gynaecol* 96:120–122. <https://doi.org/10.1111/j.1471-0528.1989.tb01589.x>.
 97. Salamon SA, Prag J. 2001. A case of superficial septic thrombophlebitis in a varicose vein caused by *Salmonella panama*. *Clin Microbiol Infect* 7:34–36. <https://doi.org/10.1046/j.1469-0691.2001.00182.x>.
 98. Centers for Disease Control and Prevention. 2011. Multistate outbreak of *Salmonella Panama* infections linked to cantaloupe (final update). Centers for Disease Control and Prevention, Atlanta, GA.

Caisey V. Pulford, B.Sc. (Hons), is a senior Ph.D. student at the University of Liverpool, Liverpool, United Kingdom. After graduating at the top of her year with a first-class degree in tropical disease biology, she became fascinated with bacterial genomic applications in public health. For the past 3 years, she has focused on understanding the molecular epidemiology of nontyphoidal *Salmonella* that causes bloodstream infection in Africa and the French Caribbean. She has made a significant contribution to global *Salmonella* sequencing efforts, working as part of the 10,000 *Salmonella* Genomes project. Her research has received numerous awards, including the NOVA for outstanding early contributions in biology and the John Lennon Memorial Scholarship in recognition of global health research. As an early career researcher, she has contributed a first author research paper focused on *Salmonella* diversity in venomous snakes. Her ambition is to pursue a career in the surveillance of bacterial pathogens during global epidemics.



Blanca M. Perez-Sepulveda, Ph.D., is a molecular microbiologist working on invasive nontyphoidal *Salmonella* (iNTS). After completing an M.Sc. (Res) in biochemistry at the University of Chile, she moved to the United Kingdom, where she obtained a Ph.D. at the University of Warwick studying the molecular mechanisms of phage resistance. She moved to the University of Liverpool in 2016 to join Jay Hinton’s laboratory as a postdoctoral research associate. She currently focuses on understanding the virulence determinants of novel invasive *Salmonella* Enteritidis clades identified in sub-Saharan African regions, using a combination of phenotypic characterization, comparative genomics, and transcriptomics. In collaboration with the Earlham Institute, she has been leading the 10,000 *Salmonella* Genomes project, a worldwide collaborative effort to understand the transmission and virulence of iNTS. Her interests lie in understanding how bacteria survive in the environment. Her focus has been to determine the environmental reservoirs and transmission of *Salmonella* and its phages by studying molecular mechanisms of virulence and phage resistance.



Continued next page

Ella V. Rodwell, B.Sc. (Hons), is a Master of Research student at the University of Liverpool, Liverpool, United Kingdom. Her research interests lie in the molecular microbiology of bacterial pathogens during global epidemics. As an early career researcher, she has published her first research paper, which was focused on understanding reservoirs for *Salmonella* infections in Africa. Between 2015 and 2018, she completed her undergraduate studies in biological sciences at the University of West England, from which she obtained a first-class degree with honors. In 2017, she held a Microbiology Society-funded studentship within the University of Liverpool, where she focused on *Salmonella* metabolism in venomous snakes. Her current work focuses on the molecular epidemiology and characterization of prophages and their importance in driving bacterial epidemics. She has a keen interest in public health, epidemiology, and disease surveillance. Her goal is to develop treatments and control initiatives for infectious diseases.



François-Xavier Weill, M.D., Ph.D., is a clinical microbiologist and a research director at the Pasteur Institute, Paris, France. For the last 10 years, he has been heading the Enteric Bacterial Pathogens Research and Expertise Unit, which hosts two French National Reference Centers and one World Health Organization Collaborative Center. Between 2014 and 2016, he was a visiting scientist in the Bacterial Genomics and Evolution group at the Wellcome Sanger Institute, Cambridge, United Kingdom. His research interests are the population structure and transmission dynamics of emerging, epidemic, and antimicrobial drug-resistant enteric bacterial pathogens, as well as molecular and genomic epidemiology, and the development of new diagnostic tools for these pathogens. He has published over 150 peer-reviewed papers, including 55 as first or last author, in journals such as *Science*, *Nature*, *Nature Microbiology*, and *Lancet Infectious Diseases*.



Jay C. D. Hinton, B.Sc. (Hons), M.A., Ph.D., is based at the University of Liverpool, Liverpool, United Kingdom. He did his first degree in microbiology, when he was inspired to think genetically by George Salmond. After receiving his Ph.D., he moved to the University of Oxford to work on the regulation of virulence gene expression in *Salmonella* and subsequently moved to Norwich, United Kingdom, as Head of Molecular Microbiology at the Institute of Food Research. He has done bacterial functional genomics for the past 20 years. He pioneered a transcriptomic approach that revealed a “snapshot” of *Salmonella* gene expression during the process of infection of mammalian cells in 2003 and codiscovered the H-NS-mediated mechanism of silencing gene expression in bacteria in 2006. After moving to Liverpool in 2012, he now uses a combination of genomics and functional transcriptomics to bring new insights to the lethal epidemic of bloodstream infections caused by *Salmonella* in sub-Saharan Africa.

